Quantum Genomics Quantum Genomics
  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
    • Strategy
  • Science
    • Pipeline
      • Firibastat – First-in-class – hypertension as monotherapy
      • Best-in-class – optimized treatment of hypertension and heart failure
      • Hypertension in combination
      • Firibastat – First-in-class – heart failure
    • The BAPAIs
    • Scientific Publications
  • Did you know that ?
    • Did you know that ?
    • High blood pressure
    • Heart failure
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Investors presentations
    • Equity research
    • Shareholder letter
    • General meetings
    • Shareholding
    • Governance
    • Financial calendar
    • Contacts
  • News & Media
    • Press releases
    • Press/Audio
    • Videos
  • Contact us
News

August 28th: Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure

Quantum on 5 July 2021

August 28th: Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure

Read the press realease

Previous Post (p) Exclusive interview with Professor Gilles Montalescot
Next Post (n) First patient enrolled in REFREH study
Quantum 2021-07-05T08:31:30+02:00
About

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Contact us

33 rue Marbeuf
75008 Paris

[email protected]
+33(0)1 85 34 77 70

Write us

Quick access
  • Strategy
  • Pipeline
  • Did you know that ?
  • Scientific Publications
Search

 

© 2019 Quantum Genomics - Legal notice - Website terms and conditions

  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
    • Strategy
  • Science
    • Pipeline
      • Firibastat – First-in-class – hypertension as monotherapy
      • Best-in-class – optimized treatment of hypertension and heart failure
      • Hypertension in combination
      • Firibastat – First-in-class – heart failure
    • The BAPAIs
    • Scientific Publications
  • Did you know that ?
    • Did you know that ?
    • High blood pressure
    • Heart failure
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Investors presentations
    • Equity research
    • Shareholder letter
    • General meetings
    • Shareholding
    • Governance
    • Financial calendar
    • Contacts
  • News & Media
    • Press releases
    • Press/Audio
    • Videos
  • Contact us
  • Blog
  • Home
  • Contact us